Laurence Albiges
@AlbigesL
Followers
3K
Following
1K
Media
124
Statuses
294
Medical Oncologist - GU oncology; Chair Med Onc Dpmt @gustaveroussy ; Professor of medecine @UniversiteParisSaclay #kidneycancer #RCC views are mine
Joined September 2017
RT @CancerNetwrk: Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.….
cancernetwork.com
Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
0
2
0
Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works. @FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !
4
8
34
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
671
3K
9K
RT @KidneyCancer: 🎉 Excited to share that @derosa_lisa will be the Keynote Speaker at 2025 IKCS: Europe! #IKCSEU25. Don't miss her talk on….
0
6
0
Day 1 @myESMO #Preceptorship in Metastatic #urothelial #RCC #cancer .62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC @myESMO #guidelines
7
17
84
RT @myESMO: In his Keynote Lecture at #ELCC25, @BenjaminBesseMD discusses when ‘less is more,’ describing different de-escalation strategie….
0
15
0
RT @montypal: Please join @AlbigesL @g_develasco #JensBedkeMD & myself at #ESMO24 for a discussion of #kidneycancer that will span topics o….
0
15
0
RT @MRoupret: #BreakingNews Our 2023 IF is now 8.3 ! So proud of our amazing team @AlbigesL @UroDocAsh @Ric_Campi @Ecastromarcos @jteoh_hk….
0
8
0
RT @brian_rini: KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussio….
0
31
0
RT @UrologyTimes: Circulating kidney injury molecule-1 may be a biomarker for minimal residual disease, disease recurrence, and benefit fro….
urologytimes.com
Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at...
0
1
0
RT @DrChoueiri: Exciting preliminary data from Phase I/Ib study of HIF2α inhibitor DFF332 in pts w/ advanced ccRCC presented by my dear fri….
0
24
0
RT @oncologytube: Top 5 Must See Kidney and Bladder Data @montypal #ASCO24 @ASCO @AlbigesL @brian_rini @motzermd @shilpaonc @CityofHope_GU….
0
17
0
RT @PauloBergerot: Don't miss tomorrow's Rapid Oral Abstract Session - Friday 8:30. @Montypal will present the Preliminary results of.P1….
0
7
0
RT @tompowles1: Renal cancer highlights #ASCO24 KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) ⬆️ in kidney injury and is imm….
0
24
0
RT @myESMO: Updated 📢#RenalCellCarcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data….
0
31
0
RT @drenriquegrande: #ASCO24 abstracts titles are out!!!! My top 5 communications in Kidney & Bladder based on the….
0
15
0
RT @myESMO: Still time to apply 👉 #ESMOPreceptorship on Metastatic #BladderCancer & #KidneyCancer: molecular pathology & diagnosis as contr….
0
4
0
Proud of @GustaveRoussy GU group celebrating 20th anniversary #GU24 🎂.Thrilled to contribute to 20years of advances in GU cancers care !. Missing @PBlanchardMD @AlbertoBossial @drcmassard
2
9
116
RT @myESMO: The #MCCRWorkshop enables peer #mentoring and #CareerDevelopment for early-career #oncology professionals. Apply now to gain ac….
0
6
0
RT @MRoupret: Listening to "December 2023 – Eur Urol Oncology highlights" at @EurUrolOncol @Uroweb @UroDocAsh @Ric….
0
9
0